The purpose of the present study was to investigate the effect of microRNA (miR)-144-5p on human umbilical vein endothelial cells (HUVECs) to explore the role of miR-144-5p in atherosclerosis. miR-144-5p expression was upregulated in HUVECs using miR-144-5p mimics. The relative expression level of miR-144-5p in HUVECs was detected using reverse transcription-quantitative PCR (RT-qPCR). Cell proliferation was detected by performing an MTT assay. Apoptosis was determined via flow cytometry. Cell migration ability was detected by a wound-healing assay. Cell invasion was determined by a transwell assay. The protein levels of phosphorylated (p)-PI3K, p-Akt and endothelial nitric oxide synthase (eNOS) were detected using western blot analysis. The binding sites between miR-144-5p and 3′-untranslated region of rapamycin-insensitive companion of mTOR (RICTOR) mRNA were predicted by TargetScan and confirmed by a dual luciferase reporter assay. The present study showed that miR-144-5p mimics significantly inhibited cell proliferation and induced apoptosis in HUVECs. In addition, miR-144-5p mimics could suppress migration and invasion of HUVECs. Further analysis identified that RICTOR was a direct target gene of miR-144-5p. Moreover, miR-144-5p upregulation decreased the protein level of p-PI3K, p-Akt and eNOS. In conclusion, miR-144-5p regulated HUVEC proliferation, migration, invasion, and apoptosis through affecting the PI3K-Akt-eNOS signaling pathway by altering the expression of RICTOR. These results indicated that miR-144-5p may be a potential target for the prevention and treatment of atherosclerosis.
Atherosclerosis is a chronic inflammatory and vascular disease, which frequently causes heart disease and stroke (
MicroRNAs (miRNAs/miRs) are a group of small, single-stranded, non-coding RNA molecules which influence the synthesis of proteins via their interactions with target mRNAs (
Previous studies reported that several miRNAs, such as miR-34a, miR-217, and miR-146a, could regulate the proliferation and differentiation of ECs and may also stimulate cellular senescence, which can act as a trigger for endothelial dysfunction (
HUVECs were obtained from Shanghai Institute of Life Sciences, Chinese Academy of Sciences. HUVECs were cultured in medium 199 supplemented with 10% FBS, 1% penicillin and streptomycin (Gibco; Thermo Fisher Scientific, Inc.), endothelial cell growth supplement (Sigma-Aldrich; Merck KGaA) and epidermal growth factor (10 ng/ml, Roche Diagnostics) in a humidified atmosphere at 37°C with 5% CO2.
Once cells reached 70–80% confluency, miR-144-5p mimics (Guangzhou RiboBio Co., Ltd.) or the negative control of miR-144-5p mimics (mimics-NC; Guangzhou RiboBio Co., Ltd.) were transfected into HUVECs using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific Inc.) according to the manufacturer's protocols. The transfection efficiency was detected by reverse transcription-quantitative PCR (RT-qPCR), as described below.
After transfection, HUVECs were washed three times with PBS and centrifuged at 1,000 × g for 5 min at 20°C. Harvested cells were stained with 200 µl annexin V/FITC binding buffer (Beyotime Institute of Biotechnology) and then incubated with 5 µl propidium iodide (PI; Beyotime Institute of Biotechnology) for 25 min at room temperature without light. Cell apoptosis was analyzed by flow cytometry (BD FACSCalibur™; Becton, Dickinson and Company) and data were analyzed using FlowJo software (version 7.6.1; FlowJo LLC). Each experiment was performed in triplicate.
Cell invasion ability was detected using a Transwell chamber (pore size, 8 µm; Costar; Corning Inc.) pre-coated with Matrigel (1 mg/ml; BD Biosciences) at 4°C overnight. HUVECs (2×104 cells/well) were briefly plated into the upper chambers using human endothelial serum-free medium (cat. no. 11111044; Gibco; Thermo Fisher Scientific, Inc.) containing 0.5% FBS. Medium (DMEM; Gibco; Thermo Fisher Scientific, Inc.) containing 10% FBS was added to the lower chamber as a chemoattractant, stimulating cells to move to the lower chamber. At 24 h after incubation, the invasive cells on the lower chamber were fixed with 4% paraformaldehyde at room temperature for 30 min. Subsequently, the membrane was stained for 30 min with 0.1% crystal violet at room temperature. Cells located on the top of membrane were wiped with a cotton swab. The Transwell chamber was then washed with 95% ethanol. A total of 10 fields of view were selected randomly to count the number of cells under a light microscope (magnification, ×200; Nikon Corporation). Each group was repeated in triplicate and all experiments were repeated three times to obtain average values.
A wound-healing assay was performed to detect cell migration ability. HUVECs (3×105 cells/well) were seeded in six-well plates. Cells were grown until 90% confluency before each well was scraped with a 10 µl pipette tip to create a linear region devoid of cells. Subsequently, the cells were washed with PBS three times. Human endothelial serum-free culture medium (cat. no. 11111044; Gibco; Thermo Fisher Scientific, Inc.) was then added to cells and incubated at 37°C with 5% CO2. Wound healing was monitored using a light microscope (magnification, ×100; Nikon Corporation) at 0 and 24 h after scraping. Percentage of wound (%) = (Wound width at 24 h/Wound width at 0 h) ×100.
HUVECs were inoculated in a 96-well plate at a density of 1×104 cells/well at 37°C with 5% CO2 for 12, 24 and 48 h. Subsequently, MTT (20 µl; 5 mg/ml) was added to each well, and cells were incubated for 4 h. A total of 150 µl DMSO was added to dissolve formazan crystals and gently shaken for 10 min. The optical density of each sample was determined with a microplate reader (Multiskan™ FC; Thermo Fisher Scientific, Inc.) by measuring the absorbance at 490 nm. The experiments were repeated at least three times.
Total protein was extracted from HUVECs using radioimmunoprecipitation assay buffer containing 1 mM PMSF. Bicinchoninic Acid Protein assay kit (Thermo Fisher Scientific, Inc.) was then used to quantify protein concentration following which the protein samples were separated by 10% SDS-PAGE (20 µg/lane) and transferred onto PVDF membranes. Subsequently, the membrane was blocked with 5% skim milk for 1 h at room temperature and incubated with primary antibodies against phosphorylated (p)-AKT (cat. no. ab81283; 1:1,000; Abcam), AKT (cat. no. ab179463, 1:10,000, Abcam), p-PI3K (cat. no. ab182651, 1:1,000, Abcam), PI3K (cat. no. ab86714, 1:1,000, Abcam), eNOS (cat. no. ab66127, 1:1,000, Abcam) or GAPDH (cat. no. ab181602, 1:10,000, Abcam) at 4°C overnight. The membrane was then incubated with horseradish peroxidase-conjugated secondary antibody Goat Anti-Rabbit IgG H&L (ab205718; 1:2,000; Abcam), Goat Anti-Mouse IgG H&L (ab205719; 1:2,000; Abcam) and for 2 h at room temperature. The GAPDH was used as internal reference. Afterwards, the protein bands were detected and visualized using an enhanced chemiluminescence method (RapidStep™ ECL Reagent; Merck KGaA). The densities of bands were semi-quantitively analyzed using ImageJ (version 4.0; National Institutes of Health).
Total RNA was extracted from HUVECs using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.) following the manufacturer's protocols. Total RNA concentration was detected by NanoDrop™ 2000 (Thermo Fisher Scientific, Inc.) and RNA samples were subsequently stored at −80°C. cDNA synthesis was performed using the RevertAid™ First Strand cDNA Synthesis kit (Thermo Fisher Scientific, Inc.). The temperature protocol was as follows: 42°C for 30 min and 85°C for 5 min. RT-qPCR was performed using a QuantiFast SYBR Green PCR kit (Qiagen GmbH) in accordance with the manufacturer's protocols. The following primers were used: U6 forward, 5′-GCTTCGGCAGCACATATACTAAAAT-3′ and reverse, 5′-CGCTTCACGAATTTGCGTGTCAT-3′; miR-144-5p forward, 5′-GCGCGAATTCGAGATCTTAACAGACCCTAGCTC-3′ and reverse, 5′-GCGCGGATCCGTGCCCTGGCAGTCAGTAGG-3′. Relative expression levels were calculated using the 2−ΔΔCq method (
TargetScan 7.2 (
All data were are presented as the mean ± standard deviation. All experiments were performed at least three times. SPSS 19.0 software (IBM Corp.) was used to perform data analysis. Comparisons between groups were analyzed using Student's t-test and one-way analysis of variance followed by Tukey's post hoc test. P<0.05 was considered to indicate a statistically significant difference.
An RT-qPCR assay was first performed to detect the transfection efficiency of miR-144-5p. RT-qPCR results showed that miR-144-5p mimics significantly increased the relative expression of miR-144-5p in HUVECs compared with the mimic-NC (
In order to investigate the migration and invasion of cells in different groups, wound healing and transwell assays were performed. Results from the wound healing assay revealed that miR-144-5p mimics significantly inhibited the cell migration ability of HUVECs compared with the mimic-NC group (
To investigate the potential role of miR-144-5p in the growth of HUVECs, bioinformatics analysis was performed to predict the potential targets of miR-144-5p. The results identified binding sites between the 3′-UTR of RICTOR and miR-144-5p (
In order to further explore the specific mechanism of the effect of miR-144-5p on HUVECs, the expression levels of related proteins in the PI3K-Akt-eNOS pathway were detected. Results from the western blot analysis indicated that miR-144-5p mimics decreased the protein levels of phosphorylated (p)-PI3K, p-Akt and eNOS in HUVECs (
Atherosclerosis is a relatively complex disease affecting medium and large-sized arteries. Vascular injury plays and important role in the pathogenesis of atherosclerosis, and endothelial apoptosis plays a crucial role in endothelial dysfunction and atherosclerosis lesion formation (
Previously, miRNAs have been confirmed to be involved in numerous important physiological processes (
miR-144-5p has been studied in various cancers such as renal cell carcinoma (
The effect of miR-144-5p upregulation on the biological behaviors of HUVECs was determined by performing MTT, migration and invasion assays, and flow cytometry. The results demonstrated that miR-144-5p mimics significantly inhibited HUVEC proliferation, migration and invasion, and induced cell apoptosis.
Subsequently, to explore the underlying mechanism of miR-144-5p on HUVECs, bioinformatics analysis was used to predict the potential targets of miR-144-5p. RICTOR was a direct target of miR-144-5p in HUVECs. RICTOR is a crucial component of mTOR complex 2 (mTORC2), and the activation of mTORC2 depends on the presence of the RICTOR protein. In addition, RICTOR is required for the inactivating Ser473 phosphorylation on Akt (
In conclusion, miR-144-5p inhibited the proliferation, invasion and migration of HUVECs, and induced apoptosis through regulating the PI3K-Akt-eNOS signaling pathway, at least partly by modulating RICTOR expression. Thus, miR-144-5p might participate in the occurrence and development of atherosclerosis through regulating the apoptosis of ECs. However, the current study only included a preliminary analysis of miR-144-5p in atherosclerosis. To completely elucidate the role of miR-144-5p in atherosclerosis, further in-depth research is needed. For example, the protective effects of RICTOR, PI3K, Akt, and eNOS on HUVECs should be investigated. The role of miR-144-5p in atherosclerosis should be studied
Not applicable.
No funding was received.
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
ZL designed the study and revised the manuscript. WF and JZ wrote the manuscript and collected the data. YS and RZ searched the literature and interpreted the data. HZ collected the data. All authors read and approved the final manuscript.
Not applicable.
Not applicable.
The authors declare that they have no competing interests.
miR-144-5p suppresses cell proliferation and promotes apoptosis. (A) A reverse transcription-quantitative PCR assay detected the relative expression of miR-144-5p in HUVECs transfected with miR-144-5p mimic or mimic-NC for 48 h. (B) An MTT assay was performed to determine the proliferation in HUVECs transfected with miR-144-5p mimics or mimics-NC for 48 h. (C) A flow cytometry assay was performed to determine apoptosis in HUVECs transfected with miR-144-5p mimics or mimics-NC for 48 h. (D) Apoptotic rate of transfected cells compared with non-transfected cells. **P<0.01 vs. mimic-NC. NC, negative control; miR, microRNA.
miR-144-5p mimics suppress cell migration and invasion of HUVECs. (A) A wound healing assay was performed to determine cell migration in HUVECs transfected with miR-144 mimic or mimic-NC for 24 h. Scale bars, 50 µm. (B) Percentage of wound data are presented as the mean ± SD from three independent experiments. (C) A Transwell assay was performed to determine cell invasion in HUVECs transfected with miR-144-5p mimics or mimic-NC for 24 h (magnification, ×200). (D) The number of invaded cells was calculated and presented as the mean ± SD from three independent experiments. **P<0.01 vs. mimic-NC. NC, negative control; miR, microRNA.
RICTOR is a direct target gene of miR-144-5p. (A) Binding sites between miR-144-5p and RICTOR. (B) A dual-luciferase reporter assay was used to confirm the binding sites between miR-144-5p and RICTOR in HUVECs. **P<0.01 vs. mimic-NC. RICTOR, rapamycin-insensitive companion of mTOR; UTR, untranslated region; NC, negative control; miR, microRNA; WT, wild-type.
miR-144-5p mimics inhibit the protein levels of p-PI3K, p-Akt and eNOS. (A) Western blot assay detected the protein levels of p-PI3K, PI3K, p-Akt, Akt and eNOS, and GAPDH was used as an internal control. (B) Ratios of p-PI3K/PI3K, p-Akt/Akt, and eNOS/GAPDH were calculated. **P<0.01 vs. mimic-NC eNOS, endothelial nitric oxide synthase; NC, negative control; miR, microRNA.